H. Lee Moffitt Cancer Center and Research Institute: Melanoma trials

The registry lists 37 Melanoma studies with H. Lee Moffitt Cancer Center and Research Institute as lead sponsor. 3 are open to participants now and 12 have results posted.

Early Phase 1 5Phase 1 18Phase 2 15No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Clinical Trial of CD40L-augmented TIL for Patients With Advanced MelanomaRecruitingNCT06961357Phase 1/2
• Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced MelanomaRecruitingNCT06295159Phase 2
• Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in MelanomaRecruitingNCT04741997Early Phase 1
• Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma PatientsCompletedNCT04526730Phase 2Results posted
• Avadomide (CC-122) in Combination With Nivolumab in Advanced MelanomaCompletedNCT03834623Phase 2Results posted
• Using MC1R Genotype to Impact Melanoma Risk BehaviorCompletedNCT03509467Not applicableResults posted
• Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV MelanomaCompletedNCT02032810Phase 1Results posted
• Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets PtsCompletedNCT01701674Not applicableResults posted
• Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic MelanomaCompletedNCT01659151Phase 2Results posted
• Yervoy With Sylatron Unresectable Stage 3 or 4 MelanomaCompletedNCT01496807Phase 1Results posted
• Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LCTerminatedNCT01437605Phase 2Results posted
• Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic MelanomaCompletedNCT01005745Not applicableResults posted
• Phase II Trial Of ZK-EPO (ZK 219477) (Sagopilone) In Metastatic MelanomaCompletedNCT00598507Phase 2Results posted
• A Phase I/II Study of Dasatinib and DacarbazineCompletedNCT00597038Phase 1/2Results posted
• Universal Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)-Producing and CD40L Expressing Bystander Cell Line for Tumor Vaccine in MelanomaCompletedNCT00101166Phase 2Results posted
• Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain MetastasesCompletedNCT05704933Early Phase 1
• Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory MelanomaCompletedNCT05628883Phase 1
• Exercise to Boost Response to Checkpoint Blockade ImmunotherapyActive, not recruitingNCT05358938Early Phase 1
• Axitinib + Ipilimumab in Advanced MelanomaActive, not recruitingNCT04996823Phase 2
• IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma PatientsActive, not recruitingNCT04562129Phase 2
• Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant MelanomaActive, not recruitingNCT03543969Early Phase 1
• Study of Trametinib + Ceritinib in Patients With Unresectable MelanomaCompletedNCT03501368Phase 1
• XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV MelanomaActive, not recruitingNCT02721459Phase 1
• Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic MelanomaCompletedNCT02652455Early Phase 1
• Biomarker Correlates of Hypoxia in Metastatic MelanomaWithdrawnNCT02061007Phase 2
• Detection of Immune Cell Infiltration Into Melanomas Treated by PV-10, a Feasibility StudyCompletedNCT01760499Phase 1
• Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV MelanomaCompletedNCT01657591Phase 1
• Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV MelanomaCompletedNCT01176474Phase 1
• Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558CompletedNCT01176461Phase 1
• Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100CompletedNCT01008527Phase 1
• Adenovirus CCL-21 Transduced MART-1/gp100/Tyrosinase/NY-ESO-1 Peptide-Pulsed Dendritic Cells MaturedCompletedNCT00798629Phase 1
• A Phase I/II Study of Sunitinib and DacarbazineTerminatedNCT00496223Phase 1/2
• Phase I/II Trial of Valproic Acid and Karenitecin for MelanomaTerminatedNCT00358319Phase 1/2
• Phase I Trial of Intratumoral pIL-12 Electroporation in Malignant MelanomaCompletedNCT00323206Not applicable
• Dendritic Cell Vaccination During Lymphoid ReconstructionCompletedNCT00313508Phase 1
• Bleomycin With or Without Electroporation Therapy in Treating Patients With Stage III or Stage IV MelanomaStatus unknownNCT00006035Phase 1
• Post-Operative Adjuvant Radiotherapy With Concurrent Interferon-AlfaCompletedNCT00005615Phase 1/2